Sort
23,748 grants matching “melanoma”
PDX Core
$177,298Meenhard Herlyn · Wistar Institute · U54 · FY2024 · CA
Pathology Core
$177,285David E E Elder · Wistar Institute · P01 · FY2010 · CA
Novel Strategy to Augmenting Immunotherapy against Melanoma
$177,259Jin-Ming Yang · University Of Kentucky · R21 · FY2024 · CA
Mechanochemical studies of adenovirus cell entry
$177,250Glen R. Nemerow · Scripps Research Institute, The · R21 · FY2016 · AI
Immunotherapy to Mitigate the Negative Effects of Alcohol on Cancer Progression
$177,182Hui Zhang · Washington State University · R21 · FY2015 · AA
Project 3: MITF in Drug Resistance and Metabolism in Melanoma
$177,178Jeffrey W Smith · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2017 · CA
Cancer Biostatistics (CB)
$177,177Kenneth Michael Boucher · University Of Utah · P30 · FY2023 · CA
Community Outreach and Engagement
$177,172Linda Barry Robertson · University Of Pittsburgh At Pittsburgh · P30 · FY2020 · CA
Novel Micro/nanofluidic Electroporation Devices for DNA&Oligonucleotide Delivery
$177,136Ly James Lee · Ohio State University · R21 · FY2007 · EB
Dissecting mechanisms of immunotherapy resistance in melanoma patients
$177,120Benjamin Izar · Dana-Farber Cancer Inst · K08 · FY2018 · CA
Dissecting mechanisms of immunotherapy resistance in melanoma patients
$177,120Benjamin Izar · Dana-Farber Cancer Inst · K08 · FY2017 · CA
Discovery of fused heterocyclic pyrazine based novel anti-mitotic agents for metastatic melanoma
$177,058Souvik Banerjee · Middle Tennessee State University · R16 · FY2024 · GM
Chemical Inhibitors of Anti-Apoptotic Bcl-2 Family Proteins
$177,030Maurizio Pellecchia · Sanford Burnham Prebys Medical Discovery Institute · U19 · FY2009 · CA
A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions
$177,000Eliezer M Van Allen · Dana-Farber Cancer Inst · R21 · FY2020 · CA
Targeting scramblase TMEM16F to break T cell exhaustion
$177,000Florian Winau · Boston Children'S Hospital · R21 · FY2019 · AI
Overcoming drug resistance using small molecule activators of protein phosphatase 2A
$176,961Jennifer D Black · University Of Nebraska Medical Center · R21 · FY2023 · CA
Ultrasensitive FACTT assays for serum biomarkers
$176,927Xiaowei Xu · University Of Pennsylvania · R21 · FY2007 · CA
Modulation of Bone Morphogenic Protein signaling for cancer immunotherapy
$176,853Piotr J Kraj · Augusta University · R21 · FY2013 · AI
DEVELOPMENTAL RESEARCH PROGRAM
$176,818Elizabeth A Grimm · University Of Tx Md Anderson Can Ctr · P50 · FY2006 · CA
DEVELOPMENTAL RESEARCH PROGRAM
$176,818University Of Texas Md Anderson Can Ctr · P50 · FY2005 · CA
DEVELOPMENTAL RESEARCH PROGRAM
$176,818University Of Texas Md Anderson Can Ctr · P50 · FY2004 · CA
Overcoming therapy resistance in melanoma
$176,809Zhi Sheng · Virginia Polytechnic Inst And St Univ · R21 · FY2025 · CA
Parallel Selective Capture of Single Circulating Melanoma Cells and Integrated On-Chip Determination of Mutational Status
$176,712Robbyn Kimberly Anand · Iowa State University · R21 · FY2020 · EB
Multiple Antigen-Engineered DC Immunication & IFNa Boost for Metastatic Melanoma
$176,699Lisa Helene Butterfield · University Of Pittsburgh At Pittsburgh · P50 · FY2010 · CA
An innate immune checkpoint in cancer immunotherapy
$176,697Carla Rothlin · Yale University · R01 · FY2019 · CA